Overview

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Phase:
Phase 1
Details
Lead Sponsor:
BioAtla, Inc.